vs
Apellis Pharmaceuticals, Inc.（APLS）与TETRA TECHNOLOGIES INC（TTI）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是TETRA TECHNOLOGIES INC的1.3倍（$199.9M vs $156.3M），TETRA TECHNOLOGIES INC净利率更高（5.3% vs -29.5%，领先34.8%），TETRA TECHNOLOGIES INC同比增速更快（-0.6% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-31.9M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -4.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Tetra Tech是一家总部位于美国加利福尼亚州帕萨迪纳的咨询与工程服务企业，业务覆盖水资源、生态环境、基础设施、资源管理、能源及国际发展等领域，可提供专业咨询、工程设计、项目管理与施工管理等多元化服务。
APLS vs TTI — 直观对比
营收规模更大
APLS
是对方的1.3倍
$156.3M
营收增速更快
TTI
高出5.4%
-5.9%
净利率更高
TTI
高出34.8%
-29.5%
自由现金流更多
APLS
多$17.6M
$-31.9M
两年增速更快
APLS
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $156.3M |
| 净利润 | $-59.0M | $8.3M |
| 毛利率 | — | 24.5% |
| 营业利润率 | -25.6% | 8.2% |
| 净利率 | -29.5% | 5.3% |
| 营收同比 | -5.9% | -0.6% |
| 净利润同比 | -62.2% | 105.5% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTTI
| Q1 26 | — | $156.3M | ||
| Q4 25 | $199.9M | $146.7M | ||
| Q3 25 | $458.6M | $153.2M | ||
| Q2 25 | $178.5M | $173.9M | ||
| Q1 25 | $166.8M | $157.1M | ||
| Q4 24 | $212.5M | $134.5M | ||
| Q3 24 | $196.8M | $141.7M | ||
| Q2 24 | $199.7M | $171.9M |
净利润APLSTTI
| Q1 26 | — | $8.3M | ||
| Q4 25 | $-59.0M | $-16.5M | ||
| Q3 25 | $215.7M | $4.2M | ||
| Q2 25 | $-42.2M | $11.3M | ||
| Q1 25 | $-92.2M | $4.0M | ||
| Q4 24 | $-36.4M | $102.7M | ||
| Q3 24 | $-57.4M | $-3.0M | ||
| Q2 24 | $-37.7M | $7.6M |
毛利率APLSTTI
| Q1 26 | — | 24.5% | ||
| Q4 25 | — | 19.4% | ||
| Q3 25 | — | 23.7% | ||
| Q2 25 | — | 27.7% | ||
| Q1 25 | — | 27.3% | ||
| Q4 24 | — | 23.1% | ||
| Q3 24 | — | 24.3% | ||
| Q2 24 | — | 25.2% |
营业利润率APLSTTI
| Q1 26 | — | 8.2% | ||
| Q4 25 | -25.6% | -4.2% | ||
| Q3 25 | 48.7% | 7.3% | ||
| Q2 25 | -18.6% | 11.2% | ||
| Q1 25 | -50.0% | 3.2% | ||
| Q4 24 | -12.3% | 5.5% | ||
| Q3 24 | -24.0% | 8.4% | ||
| Q2 24 | -14.7% | 7.3% |
净利率APLSTTI
| Q1 26 | — | 5.3% | ||
| Q4 25 | -29.5% | -11.3% | ||
| Q3 25 | 47.0% | 2.7% | ||
| Q2 25 | -23.6% | 6.5% | ||
| Q1 25 | -55.3% | 2.6% | ||
| Q4 24 | -17.1% | 76.4% | ||
| Q3 24 | -29.2% | -2.1% | ||
| Q2 24 | -18.9% | 4.4% |
每股收益（稀释后）APLSTTI
| Q1 26 | — | — | ||
| Q4 25 | $-0.40 | $-0.12 | ||
| Q3 25 | $1.67 | $0.03 | ||
| Q2 25 | $-0.33 | $0.08 | ||
| Q1 25 | $-0.74 | $0.03 | ||
| Q4 24 | $-0.30 | $0.77 | ||
| Q3 24 | $-0.46 | $-0.02 | ||
| Q2 24 | $-0.30 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $35.5M |
| 总债务越低越好 | — | $5.9M |
| 股东权益账面价值 | $370.1M | $285.6M |
| 总资产 | $1.1B | $662.3M |
| 负债/权益比越低杠杆越低 | — | 0.02× |
8季度趋势，按日历期对齐
现金及短期投资APLSTTI
| Q1 26 | — | $35.5M | ||
| Q4 25 | $466.2M | $72.6M | ||
| Q3 25 | $479.2M | $67.1M | ||
| Q2 25 | $370.0M | $68.7M | ||
| Q1 25 | $358.4M | $41.0M | ||
| Q4 24 | $411.3M | $37.0M | ||
| Q3 24 | $396.9M | $48.4M | ||
| Q2 24 | $360.1M | $37.7M |
总债务APLSTTI
| Q1 26 | — | $5.9M | ||
| Q4 25 | — | $190.0M | ||
| Q3 25 | — | $180.9M | ||
| Q2 25 | — | $180.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $179.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $179.7M |
股东权益APLSTTI
| Q1 26 | — | $285.6M | ||
| Q4 25 | $370.1M | $283.8M | ||
| Q3 25 | $401.2M | $296.7M | ||
| Q2 25 | $156.3M | $290.9M | ||
| Q1 25 | $164.2M | $273.0M | ||
| Q4 24 | $228.5M | $254.6M | ||
| Q3 24 | $237.1M | $156.7M | ||
| Q2 24 | $264.3M | $154.8M |
总资产APLSTTI
| Q1 26 | — | $662.3M | ||
| Q4 25 | $1.1B | $675.8M | ||
| Q3 25 | $1.1B | $655.2M | ||
| Q2 25 | $821.4M | $645.6M | ||
| Q1 25 | $807.3M | $614.1M | ||
| Q4 24 | $885.1M | $605.2M | ||
| Q3 24 | $901.9M | $501.2M | ||
| Q2 24 | $904.5M | $605.2M |
负债/权益比APLSTTI
| Q1 26 | — | 0.02× | ||
| Q4 25 | — | 0.67× | ||
| Q3 25 | — | 0.61× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.71× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-31.9M |
| 自由现金流率自由现金流/营收 | -7.1% | -20.4% |
| 资本支出强度资本支出/营收 | 0.1% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $1.6M |
8季度趋势，按日历期对齐
经营现金流APLSTTI
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $31.7M | ||
| Q3 25 | $108.5M | $16.4M | ||
| Q2 25 | $4.4M | $48.3M | ||
| Q1 25 | $-53.4M | $3.9M | ||
| Q4 24 | $19.4M | $5.6M | ||
| Q3 24 | $34.1M | $19.9M | ||
| Q2 24 | $-8.3M | $24.8M |
自由现金流APLSTTI
| Q1 26 | — | $-31.9M | ||
| Q4 25 | $-14.3M | $4.1M | ||
| Q3 25 | $108.3M | $627.0K | ||
| Q2 25 | $4.4M | $28.8M | ||
| Q1 25 | $-53.4M | $-14.0M | ||
| Q4 24 | $19.3M | $-9.3M | ||
| Q3 24 | — | $5.3M | ||
| Q2 24 | $-8.4M | $9.4M |
自由现金流率APLSTTI
| Q1 26 | — | -20.4% | ||
| Q4 25 | -7.1% | 2.8% | ||
| Q3 25 | 23.6% | 0.4% | ||
| Q2 25 | 2.5% | 16.6% | ||
| Q1 25 | -32.0% | -8.9% | ||
| Q4 24 | 9.1% | -6.9% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | -4.2% | 5.5% |
资本支出强度APLSTTI
| Q1 26 | — | 4.5% | ||
| Q4 25 | 0.1% | 18.8% | ||
| Q3 25 | 0.0% | 10.3% | ||
| Q2 25 | 0.0% | 11.2% | ||
| Q1 25 | 0.0% | 11.4% | ||
| Q4 24 | 0.0% | 11.1% | ||
| Q3 24 | 0.0% | 10.3% | ||
| Q2 24 | 0.0% | 9.0% |
现金转化率APLSTTI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 3.94× | ||
| Q2 25 | — | 4.28× | ||
| Q1 25 | — | 0.97× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TTI
暂无分部数据
